Tumor Marker Patterns in Testicular Cancer
In testicular cancer, AFP and β-hCG are the primary diagnostic tumor markers with distinct histologic associations, while LDH serves as a nonspecific prognostic indicator—AFP is elevated in nonseminomatous tumors (particularly yolk sac tumors), β-hCG can be elevated in both seminomas and nonseminomas (especially choriocarcinoma), and LDH elevation correlates with tumor burden but lacks specificity.
Specific Marker Patterns by Histology
Alpha-Fetoprotein (AFP)
- Never elevated in pure seminoma 1, 2
- Highly elevated in yolk sac tumor elements 3
- Present in 67% of advanced nonseminomatous germ cell tumors (NSGCT) 3
- Critical caveat: Mildly elevated AFP (<20 ng/mL) may not indicate germ cell tumor and should not drive treatment decisions alone 1
- More highly elevated AFP levels generally indicate nonseminomatous elements 1
Beta-Human Chorionic Gonadotropin (β-hCG)
- Can be elevated in both seminomas and nonseminomas 1, 2
- Markedly elevated in choriocarcinoma 3
- Present in 64% of advanced NSGCT 3
- Important pitfall: False-positive elevations can occur with hypogonadism and cannabis use, particularly at levels <20 IU/L 1
- Further workup should be considered before treating based solely on mildly elevated β-hCG 1
Lactate Dehydrogenase (LDH)
- Nonspecific marker elevated in 62% of advanced NSGCT 3
- Reflects tumor burden rather than specific histology 4
- Can be elevated in other conditions (liver disease, tissue damage) 5
- Critical limitation: Patients should not be treated based on elevated LDH alone 1
- LDH-1 isoenzyme (encoded by LDHB gene) is particularly elevated in testicular germ cell tumors 6, 7
Clinical Utility Framework
At Diagnosis
At least one of these three markers is elevated in 91% of patients with advanced nonseminomatous disease 3. The combination provides maximum diagnostic sensitivity 8.
For Staging and Prognosis
The International Germ Cell Cancer Collaborative Group (IGCCCG) classification uses specific thresholds 2:
Good Prognosis (Nonseminoma):
- AFP <1000 ng/mL
- β-hCG <5000 IU/L
- LDH <1.5× upper limit of normal (ULN)
Intermediate Prognosis (Nonseminoma):
- AFP 1000–10,000 ng/mL, OR
- β-hCG 5000–50,000 IU/L, OR
- LDH 1.5–10× ULN
Poor Prognosis (Nonseminoma):
- AFP >10,000 ng/mL, OR
- β-hCG >50,000 IU/L, OR
- LDH >10× ULN
Special Considerations for Seminoma
β-hCG and LDH may be elevated in seminoma, but these levels alone should not be used to stage or risk-stratify patients with pure seminoma 1. Normal AFP is mandatory for seminoma classification—any AFP elevation suggests nonseminomatous elements 2.
Monitoring and Surveillance
During Treatment
- Markers should be measured immediately before each chemotherapy cycle 2
- Sustained or rising AFP or β-hCG always indicates persistent or recurrent tumor 3
- Marker increases during or shortly after chemotherapy indicate poor prognosis and necessitate immediate salvage therapy 9
Surveillance Limitations
Only 40–50% of relapses in stage I disease and 30% after chemotherapy are associated with marker increases 9. The remainder require imaging or present with clinical symptoms, emphasizing that normal markers do not exclude recurrence.
Post-Treatment
Residual masses require surgical resection once markers normalize or plateau 9. "Desperation surgery" with rising markers is only indicated when no curative chemotherapy remains available, complete resection is feasible, and β-hCG is not elevated 9.